PMID- 19235017
OWN - NLM
STAT- MEDLINE
DCOM- 20090414
LR  - 20220318
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 50
IP  - 2
DP  - 2009 Feb
TI  - HLA risk markers for chronic myelogenous leukemia in Eastern Canada.
PG  - 254-9
LID - 10.1080/10428190802668873 [doi]
AB  - Chronic myelogenous leukemia (CML) results from a translocation (9;22), which 
      creates an immunogenically active BCR-ABL fusion protein. Previous authors have 
      reported both positive and negative human leukocyte antigen (HLA) associations 
      with CML, possibly as the result of different antigenic peptide presentation 
      capabilities. We examined HLA Class I and Class II antigen polymorphisms in 31 
      patients with CML and compared these with 258 control individuals drawn from 
      Maritime Canada. HLA-B*13 (odds ratios (OR) 4.92, 95% confidence intervals (CI) 
      1.70-14.24), HLA-B*55 (OR 4.50, 95%CI 1.07-18.99), and HLA-DRB1*16 (OR 4.07, 
      95%CI 1.17-14.09) were all statistically significant risk markers for CML. After 
      a Bonferroni correction for Type I error was applied, only HLA-B*13 remained 
      statistically significant as a risk marker for CML. No HLA antigens were found to 
      be protective. The lack of reproducibility of HLA antigen associations with CML 
      suggests that these associations are population-specific and may not be due to 
      HLA antigen-restricted differences in CML antigen presentation.
FAU - Naugler, Christopher
AU  - Naugler C
AD  - Department of Pathology and Laboratory Medicine, Dalhousie University, Halifax, 
      NS, Canada.
FAU - Liwski, Robert
AU  - Liwski R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/*immunology/*metabolism
MH  - Canada/epidemiology
MH  - HLA Antigens/*immunology/*metabolism
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL 
      Positive/*epidemiology/*immunology/metabolism
MH  - Risk Factors
EDAT- 2009/02/24 09:00
MHDA- 2009/04/15 09:00
CRDT- 2009/02/24 09:00
PHST- 2009/02/24 09:00 [entrez]
PHST- 2009/02/24 09:00 [pubmed]
PHST- 2009/04/15 09:00 [medline]
AID - 908860063 [pii]
AID - 10.1080/10428190802668873 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2009 Feb;50(2):254-9. doi: 10.1080/10428190802668873.